Company intelligence / Profile preview

Afaxys

Ownership: Private
Employees: ~175
Development stage: Commercial

Overview

Afaxys offers a broad portfolio of FDA-approved branded and generic oral and emergency contraceptives as well as a contraceptive patch and injectable anesthetic. The company serves over 8,400 public health centers in the U.S. with stable pricing. It has one new form of contraception currently in development but details are undisclosed.

Therapeutic areas: Women's Health
Modalities: Small molecules (oral contraceptives, emergency contraceptives)Patch-based delivery systemsInjectable anesthetics (lidocaine)
Industry: Biotech

Drug pipeline

1 asset

levonorgestrel

Approved

Partnerships

Bayer Pharmaceuticals co-promotion to expand IUD access in public/community health centersFamy Care contract manufacturing agreementProdigo eMarketplace partnership via GPO/emapp platform

Beyond the preview

Go deeper on Afaxys.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Afaxys.

Explore the full profile